T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy

Solid tumors that are responsible for more than 85% of cancer death cases need angiogenesis for their growth and metastasis. Among antiangiogenic therapies, targeting the vascular endothelial growth factor receptor 2 (VEGFR2) that is over‐expressed on tumor vasculatures has been a promising strategy. In this study, we developed a second generation nanobody (VHH)‐based CAR T cell targeting VEGFR2‐expressing tumor cells. The CAR T cell was developed by linking the anti‐VEGFR2 VHH to a spacer, and signaling domains of CD28 and CD3 ζ. The T cells were activated with anti‐CD3 plus rIL‐2 and electroporated with a plasmid encoding the CAR construct. The expression of activation markers, CD69 and CD25, on CAR T cells upon coculturing with VEGFR2‐expressing cells were 41% and 48%, and the IL‐2 and IFN‐γ production were 470 pg/mL and 360 pg/mL, respectively. The expression of degranulation marker, CD107a, was 30% and the cytotoxic activity of the CAR T cells reached to more than 30% with E:T ratio of 9:1. The anti‐VEGFR2 CAR but not mock T cells mediated specific lysis of 293‐KDR cells expressing human VEGFR2 and might be considered as a candidate for adoptive T‐cell immunotherapy of solid tumors. © 2019 IUBMB Life, 71(9):1259–1267, 2019